Carla Marie (Lichtenberger) Nester MD MSA, FASN
Professor of Internal Medicine and Pediatrics, University Iowa,Carver College of Medicine
Join to View Full Profile
285 Newton Road5294 CBRBIowa City, IA 52241
Phone+1 319-335-2214
Fax+1 319-384-9616
Dr. Nester is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of North Carolina HospitalsFellowship, Nephrology, 2003 - 2007- University of North Carolina HospitalsFellowship, Pediatric Nephrology, 2003 - 2007
- University of North Carolina HospitalsResidency, Internal Medicine/Pediatrics, 1998 - 2002
Pennsylvania State University College of MedicineClass of 1998
Certifications & Licensure
IA State Medical License 2007 - 2025
NC State Medical License 1999 - 2007
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Nephrology
American Board of Pediatrics Pediatrics- American Board of Pediatrics Pediatric Nephrology
Publications & Presentations
PubMed
- 1 citationsIptacopan Reduces Proteinuria and Stabilizes Kidney Function in C3 Glomerulopathy.Carla M Nester, Ute Eisenberger, Alexandre Karras, Moglie le Quintrec, Liz Lightstone
Kidney International Reports. 2025-02-01 - Extrarenal manifestations of atypical hemolytic uremic syndrome: a systematic review and meta-analysis.Kush Doshi, Abdel Yusuf, Christoph Licht, Olivia Boyer, Carla Nester
Pediatric Research. 2024-12-15 - 6 citationsAn expert discussion on the atypical hemolytic uremic syndrome nomenclature-identifying a road map to precision: a report of a National Kidney Foundation Working Group.Carla M Nester, David L Feldman, Richard Burwick, Spero Cataland, Shruti Chaturvedi
Kidney International. 2024-09-01
Press Mentions
First Drug Approved for Ultra-Rare Kidney DiseaseMarch 21st, 2025- Novartis Oral Fabhalta Secures USFDA Okay for Adults with C3 GlomerulopathyMarch 20th, 2025
- Novartis Receives Third FDA Approval for Oral Fabhalta® (Iptacopan) – the First and Only Treatment Approved in C3 Glomerulopathy (C3G)March 20th, 2025
- Join now to see all
Grant Support
- C3 Glomerulopathy -- A Collaborative StudyUNIVERSITY OF IOWA2017–2027
- C3 Glomerulopathy -- A Collaborative StudyUNIVERSITY OF IOWA2017–2027
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
